Agilent Technologies, Inc. (A) Earnings Call Transcripts

Agilent Technologies, Inc.'s Latest Earnings Call - September 23, 2026

In Agilent Technologies' fiscal Q3 2026 earnings call, the company reported strong performance with revenue growth driven by robust demand in China and a continuation of the instrument replacement cycle. Revenue for the quarter was noted as strong, with management indicating a significant increase in earnings per share (EPS) to 10% growth compared to a 3% decline two years prior. Management raised guidance for China and indicated a positive outlook for the fourth quarter, suggesting sustained momentum in key markets, particularly in pharmaceuticals and diagnostics.

Reported metrics

Guidance from management

Management raised guidance for China, projecting it to be a 'mid-high single-digit grower' long-term. They maintained their margin expansion target of '50 to 100 basis points' for the upcoming year, despite the expected dilution from the Train C ramp-up.

What management said

Yes. I mean I think Padraig covered it nicely. I think the only piece I would add is we do have good visibility into our medium-term forecast. We have customers take time to develop their processes, et cetera, and then they put in their forecast. So it's not based on any 1 or 2 changes in a near-term period that impacts us. The second thing I would highlight, which I think is underappreciated is actually the cross-se...

Yes. So a couple of pieces. So as it's coming online now, no impact to '26. '27, it will be dilutive, of course, but we've committed to our 50 to 100 basis points that you have in the continuing to deliver that, and it goes back to Padraig's first comments about the Ignite operating system. And what we've done is we've seen this coming, we've seen the dilution coming. So you have to hire, you have to start to depreci...

What analysts pressed on

Analysts expressed concerns regarding the visibility of growth in Europe, particularly in light of geopolitical tensions and challenging comparisons. There were also questions about the sustainability of growth in the Advanced Therapeutics segment given recent negative clinical trial news in the industry.

Main topics on the call

• Strong Growth in China — Agilent reported 'double-digit growth in pharma and food' and 'high-teens growth in Advanced Materials' in China, highlighting broad-based strength across markets. Management expressed confidence in China's long-term gro...
• Instrument Replacement Cycle — The company noted 'low double-digit growth in LC' and emphasized that they are 'less than halfway through' the replacement cycle, which is expected to contribute 200 to 300 basis points to overall business growth. This c...
• Advanced Therapeutics Growth — Agilent's Advanced Therapeutics segment saw a '30% growth' in Q3, which was 'in line with expectations.' Management anticipates mid-teens growth over the long term, bolstered by a strong pipeline and customer diversifica...
• Reshoring Opportunities — Management highlighted a 'derisking' of reshoring estimates, reporting '17 MFN deals' compared to '11' previously. They expect to capture about 'one-third of a $1 billion revenue opportunity' by 2030, indicating strong c...

Read the full Agilent Technologies, Inc. transcript (September 23, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 78 Agilent Technologies, Inc. earnings call transcripts on record, spanning January 14, 2020 to September 23, 2026. Based on this history, Agilent Technologies, Inc. reports quarterly. The most recent call on file is dated September 23, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

A

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

78

First call

January 14, 2020

Most recent

September 23, 2026

Reporting cadence

quarterly